SCHEMBL24306243

SCHEMBL24306243

N#Cc1ccc(NC[C@@H]2CCO2)c(N)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.48
▸ KDM4E B2RXH2 7/20 0.48
▸ GAA P10253 6/20 0.48
▸ EGLN2 Q96KS0 1/20 0.40
▸ KMT2A Q03164 3/20 0.37
▸ HPGD P15428 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ HCAR3 P49019 1/20 0.36
▸ NAMPT P43490 3/20 0.35
▸ RAB9A P51151 3/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ CHEK1 O14757 2/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ MAPT P10636 1/20 0.34
▸ KDM1A O60341 1/20 0.34
▸ PTGER4 P35408 1/20 0.34
▸ GLA P06280 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29586014 1.00 ALDH1A1 (0.48) ALDH1A1KDM4EGAAEGLN2KMT2A
SCHEMBL26914375 1.00 ALDH1A1 (0.48) ALDH1A1KDM4EGAAEGLN2KMT2A
SCHEMBL5881677 0.82 KDM4E (0.53) ALDH1A1KDM4EGAAEGLN2KDM1A
SCHEMBL29585778 0.80 EGLN2 (0.47) ALDH1A1KDM4EGAAEGLN2NAMPT
SCHEMBL27171156 0.80 EGLN2 (0.47) ALDH1A1KDM4EGAAEGLN2NAMPT
SCHEMBL27171158 0.80 EGLN2 (0.47) ALDH1A1KDM4EGAAEGLN2NAMPT
SCHEMBL4464361 0.79 KDM4E (0.49) ALDH1A1KDM4EGAAEGLN2KMT2A
SCHEMBL24306614 0.78 AAK1 (0.44) ALDH1A1KMT2AHPGDMEN1HCAR3
SCHEMBL24306171 0.78 KMT2A (0.39) ALDH1A1KMT2AHPGDMEN1HCAR3
SCHEMBL26914178 0.78 AAK1 (0.44) ALDH1A1KMT2AHPGDMEN1HCAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083886-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2024-03-14 — — US disclosed
US-20230391760-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-12-07 — — US disclosed
CN-116547278-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-08-04 — — CN disclosed
CN-116547279-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-08-04 — — CN disclosed
WO-2022078380-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391760-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR ALDH1A1 840/4885KDM4E 3398/4885GAA 1083/4885
US-20240083886-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR ALDH1A1 1011/4885KDM4E 3662/4885GAA 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback